Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma

被引：77

作者：

Wang, Michael ^{[1
]}

Rule, Simon ^{[2
]}

Zinzani, Pier Luigi ^{[3
]}

Goy, Andre ^{[4
]}

Casasnovas, Olivier ^{[5
]}

Smith, Stephen D. ^{[6
]}

Damaj, Gandhi ^{[7
]}

Doorduijn, Jeanette K. ^{[8
]}

Lamy, Thierry ^{[9
]}

Morschhauser, Franck ^{[10
]}

Panizo, Carlos ^{[11
]}

Shah, Bijal ^{[12
]}

Davies, Andrew ^{[13
]}

Eek, Richard ^{[14
]}

Dupuis, Jehan ^{[15
]}

Jacobsen, Eric ^{[16
]}

Kater, Arnon P. ^{[17
]}

Le Gouill, Steven ^{[18
]}

Oberic, Lucie ^{[19
]}

Robak, Tadeusz ^{[20
]}

Jain, Preetesh ^{[1
]}

Frigault, Melanie M. ^{[21
]}

Izumi, Raquel ^{[21
]}

Dorothy Nguyen ^{[21
]}

Patel, Priti ^{[21
]}

Yin, Ming ^{[21
]}

Dlugosz-Danecka, Monika ^{[22
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Plymouth Univ, Sch Med, Plymouth, Devon, England

[3] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[4] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[5] Hop Enfants, CHU Dijon, Dijon, France

[6] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA

[7] Inst Hematol Basse Normandie, Caen, France

[8] Erasmus MC, HOVON Lunenburg Lymphoma Phase Consortium 1 2, Rotterdam, Netherlands

[9] CHU Rennes, Rennes, France

[10] Univ Lille, CHU Lille, GRITA Grp Rech Formes Injectables & Technol Assoc, EA 7365, F-59000 Lille, France

[11] Clin Univ Navarra, Pamplona, Spain

[12] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[13] Univ Southampton, Canc Res UK Ctr, Fac Med, Southampton, Hants, England

[14] Border Med Oncol, Albury, Vic, Australia

[15] Hop Henri Mondor, AP HP, Unite Hemopathies Lymphoides, Creteil, France

[16] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA

[17] Univ Amsterdam, Canc Ctr Amsterdam, Amsterdam Univ Med Ctr, HOVON Lunenburg Lymphoma Phase Consortium 1 2, Amsterdam, Netherlands

[18] Hop Hotel Dieu, CHU Nantes, Nantes, France

[19] Inst Univ Canc Oncopole Toulouse, Toulouse, France

[20] Med Univ Lodz, Copernicus Mem Hosp, Lodz, Poland

[21] Acerta Pharma, San Francisco, CA USA

[22] Jagiellonian Univ, Dept Haematol, Krakow, Poland

来源：

LEUKEMIA | 2019年 / 33卷 / 11期

关键词：

IBRUTINIB;

D O I：

10.1038/s41375-019-0575-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2762 / 2766

页数：5

共 50 条

[21] Complete clinical response with single-agent high dose Rituximab in mantle cell lymphoma.
Jain, D
Dutcher, JP
Wiernik, PH
BLOOD, 2003, 102 (11) : 305B - 305B
[22] Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
Marie Maerevoet
Josee M. Zijlstra
George Follows
Rene-Olivier Casasnovas
J. S. P. Vermaat
Nagesh Kalakonda
Andre Goy
Sylvain Choquet
Eric Van Den Neste
Brian Hill
Catherine Thieblemont
Federica Cavallo
Fatima De la Cruz
John Kuruvilla
Nada Hamad
Ulrich Jaeger
Paolo Caimi
Ronit Gurion
Krzysztof Warzocha
Sameer Bakhshi
Juan-Manuel Sancho
Michael Schuster
Miklos Egyed
Fritz Offner
Theodoros P. Vassilakopoulos
Priyanka Samal
Matthew Ku
Xiwen Ma
Kelly Corona
Kamal Chamoun
Jatin Shah
Sharon Shacham
Michael G. Kauffman
Miguel Canales
Journal of Hematology & Oncology, 14
[23] Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
Maerevoet, Marie
Zijlstra, Josee M.
Follows, George
Casasnovas, Rene-Olivier
Vermaat, J. S. P.
Kalakonda, Nagesh
Goy, Andre
Choquet, Sylvain
Van den Neste, Eric
Hill, Brian
Thieblemont, Catherine
Cavallo, Federica
De la Cruz, Fatima
Kuruvilla, John
Hamad, Nada
Jaeger, Ulrich
Caimi, Paolo
Gurion, Ronit
Warzocha, Krzysztof
Bakhshi, Sameer
Sancho, Juan-Manuel
Schuster, Michael
Egyed, Miklos
Offner, Fritz
Vassilakopoulos, Theodoros P.
Samal, Priyanka
Ku, Matthew
Ma, Xiwen
Corona, Kelly
Chamoun, Kamal
Shah, Jatin
Shacham, Sharon
Kauffman, Michael G.
Canales, Miguel
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
[24] Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Lenz, Georg
Hawkes, Eliza
Verhoef, Gregor
Haioun, Corinne
Thye, Lim Soon
Heo, Dae Seog
Ardeshna, Kirit
Chong, Geoffrey
Christensen, Jacob Haaber
Shi, Vivian
Lippert, Susanne
Niemeyer, Florian
Piraino, Paolo
Pena, Carol Elaine
Buvaylo, Viktoriya
Childs, Barrett H.
Gorbatchevsky, Igor
Salles, Gilles A.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[25] Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial
Bartlett, Nancy L.
Costello, Brian A.
LaPlant, Betsy R.
Ansell, Stephen M.
Kuruvilla, John G.
Reeder, Craig B.
Thye, Lim S.
Anderson, Daniel M.
Krysiak, Kilannin
Ramirez, Cody
Qi, Jing
Siegel, Barry A.
Griffith, Malachi
Griffith, Obi L.
Gomez, Felicia
Fehniger, Todd A.
BLOOD, 2018, 131 (02) : 182 - 190
[26] Use of acalabrutinib in patients with mantle cell lymphoma
Awan, Farrukh T.
Jurczak, Wojciech
EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (06) : 495 - 502
[27] COST-EFFECTIVENESS ANALYSIS FOR ACALABRUTINIB IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (R/R MCL) IN CHINA
Chang, S.
He, X.
VALUE IN HEALTH, 2024, 27 (06) : S95 - S95
[28] Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences
Eve, Heather E.
Carey, Sean
Richardson, Sarah J.
Heise, Carla C.
Mamidipudi, Vidya
Shi, Tao
Radford, John A.
Auer, Rebecca L.
Bullard, Sheila H.
Rule, Simon A. J.
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 (02) : 154 - 163
[29] Bortezomib, rituximab,and dexamethason (BORID) induces high response ratesand durable complete remissions in patients with relapsed/refractory mantle cell lymphoma
Drach, J.
Kaufmann, H.
Pichelmayer, O.
Sagaster, V.
Seidl, S.
Zielinski, C.
Chott, A.
Raderer, M.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 435 - 435
[30] Temsirolimus In Relapsed and/or Refractory Mantle Cell Lymphoma
Hoy, Sheridan M.
McKeage, Kate
DRUGS, 2010, 70 (14) : 1819 - 1829

← 1 2 3 4 5 →